Acrivon Therapeutics Inc (ACRV)

Apr 25, 2025

ACRV’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com

Apr 25, 2025

Apr 25, 2025

Understanding ACRV stock ratios for better investment decisions - uspostnews.com

Apr 25, 2025

Apr 25, 2025

Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025 - GlobeNewswire

Apr 25, 2025

Apr 25, 2025

Breakthrough Cancer Drug ACR-2316 Achieves 25% Tumor Reduction with Zero Safety Issues in Phase 1 Trial - Stock Titan

Apr 25, 2025

Apr 23, 2025

(ACRV) On The My Stocks Page - news.stocktradersdaily.com

Apr 23, 2025

Apr 22, 2025

April 2025's Standout Penny Stocks - simplywall.st

Apr 22, 2025

Apr 20, 2025

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Up 21.4% in March - Defense World

Apr 20, 2025

Apr 16, 2025

Acrivon Therapeutics Inc’s Banking’s 100-Day Moving Average at 5.3600: Will the Stock Break Through? - investchronicle.com

Apr 16, 2025

Apr 15, 2025

ACRV’s price-to-cash ratio: How it affects the stock’s valuation. - uspostnews.com

Apr 15, 2025

Apr 14, 2025

Down -70.22% in 4 Weeks, Here's Why You Should You Buy the Dip in Acrivon Therapeutics, Inc. (ACRV) - NewsBreak: Local News & Alerts

Apr 14, 2025

Apr 08, 2025

Acrivon Therapeutics' SWOT analysis: oncology innovator's stock faces pivotal moment By Investing.com - Investing.com South Africa

Apr 08, 2025

Apr 08, 2025

Acrivon Therapeutics’ SWOT analysis: oncology innovator’s stock faces pivotal moment - Investing.com India

Apr 08, 2025

Apr 08, 2025

Acrivon Therapeutics' SWOT analysis: oncology innovator's stock faces pivotal moment - Investing.com

Apr 08, 2025

Apr 08, 2025

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $23.17 Average Price Target from Analysts - Defense World

Apr 08, 2025

Apr 07, 2025

Acrivon Therapeutics Reports Progress in Cancer Drug Development - TipRanks

Apr 07, 2025

Apr 07, 2025

Acrivon Therapeutics Appoints Mansoor Raza Mirza, M.D., as Chief Medical Officer - citybiz

Apr 07, 2025

Apr 07, 2025

Acrivon appoints new chief medical officer to advance cancer trials By Investing.com - Investing.com South Africa

Apr 07, 2025

Apr 07, 2025

Acrivon Therapeutics Appoints Mansoor Mirza as Medical Chief - marketscreener.com

Apr 07, 2025

Apr 07, 2025

Acrivon appoints new chief medical officer to advance cancer trials - Investing.com

Apr 07, 2025

Apr 07, 2025

Acrivon Therapeutics Appoints New Chief Medical Officer - TipRanks

Apr 07, 2025

Apr 07, 2025

Acrivon Therapeutics Appoints World-Renowned Oncology Key - GlobeNewswire

Apr 07, 2025

Mar 29, 2025

Q1 Earnings Forecast for ACRV Issued By HC Wainwright - Defense World

Mar 29, 2025

Mar 29, 2025

Acrivon Therapeutics (NASDAQ:ACRV) and Astellas Pharma (OTCMKTS:ALPMY) Head to Head Contrast - Defense World

Mar 29, 2025

Mar 28, 2025

H.C. Wainwright maintains Acrivon stock Buy rating, $19 target By Investing.com - Investing.com Australia

Mar 28, 2025

Mar 28, 2025

Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's What You Should Know - MSN

Mar 28, 2025

Mar 28, 2025

Acrivon Therapeutics price target lowered to $10 from $18 at Oppenheimer - TipRanks

Mar 28, 2025

Mar 28, 2025

Here's Why Acrivon Therapeutics, Inc. (ACRV) is Poised for a Turnaround After Losing -52.81% in 4 Weeks - Yahoo Finance

Mar 28, 2025

Mar 28, 2025

H.C. Wainwright maintains Acrivon stock Buy rating, $19 target - Investing.com

Mar 28, 2025

Mar 28, 2025

HC Wainwright Has Lowered Expectations for Acrivon Therapeutics (NASDAQ:ACRV) Stock Price - Defense World

Mar 28, 2025

Mar 28, 2025

FY2029 Earnings Estimate for ACRV Issued By HC Wainwright - Defense World

Mar 28, 2025

Mar 28, 2025

Cantor Fitzgerald Reaffirms “Overweight” Rating for Acrivon Therapeutics (NASDAQ:ACRV) - Defense World

Mar 28, 2025

Mar 27, 2025

Acrivon Therapeutics reports Q4 EPS (60c), consensus (70c) - TipRanks

Mar 27, 2025

Mar 27, 2025

Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire

Mar 27, 2025

Mar 27, 2025

Breakthrough: Acrivon's Cancer Drug Shows 35% Response Rate in Hard-to-Treat Endometrial Cancer - Stock Titan

Mar 27, 2025

Mar 27, 2025

Acrivon Therapeutics Reports 2024 Financial Results and Progress - TipRanks

Mar 27, 2025

Mar 27, 2025

Long Term Trading Analysis for (ACRV) - news.stocktradersdaily.com

Mar 27, 2025

Mar 27, 2025

Acrivon narrows focus for ACR-368 in endometrial cancer - BioWorld MedTech

Mar 27, 2025

Mar 27, 2025

JMP maintains Acrivon stock with $17 target following update By Investing.com - Investing.com Australia

Mar 27, 2025

Mar 26, 2025

Acrivon Therapeutics stock target cut to $19 by H.C. Wainwright - Investing.com South Africa

Mar 26, 2025

Mar 26, 2025

12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga

Mar 26, 2025

Mar 26, 2025

Crude Oil Gains Over 1%; Cintas Shares Jump After Q3 Earnings - Benzinga

Mar 26, 2025

Mar 26, 2025

Nasdaq Down 1%; Dollar Tree To Sell Family Dollar Business For $1 Billion - Benzinga

Mar 26, 2025

Mar 26, 2025

Humacyte to raise $50M; Acrivon to focus on prexasertib in endometrial cancer - Endpoints News

Mar 26, 2025

Mar 26, 2025

Cantor Fitzgerald maintains Overweight on Acrivon stock By Investing.com - Investing.com South Africa

Mar 26, 2025

Mar 26, 2025

Cantor Fitzgerald maintains Overweight on Acrivon stock - Investing.com

Mar 26, 2025

Mar 26, 2025

JMP maintains Acrivon stock with $17 target following update - Investing.com

Mar 26, 2025

Mar 26, 2025

ACRV stock touches 52-week low at $4 amid market challenges - Investing.com UK

Mar 26, 2025